Skip to main content
. Author manuscript; available in PMC: 2023 Jun 1.
Published in final edited form as: Female Pelvic Med Reconstr Surg. 2022 Apr 28;28(6):e205–e210. doi: 10.1097/SPV.0000000000001185

Figure 4: Urinary IL-6 levels in women with and without methenamine hippurate treatment.

Figure 4:

Filled dots: women without MH, VET, or DM prophylaxis (NP)

Empty squares: women receiving MH alone (MH)

Filled triangles: women receiving VET and/or DM (VET±DM)

Empty triangles: women receiving MH in addition to VET and/or DM (MH + VET±DM)

There was no significant difference in urinary IL-6 levels between A) women receiving no prophylaxis with MH, DM, or VET (NP) versus those receiving MH alone (MH); B) women receiving VET and/or DM (VET±DM) versus those receiving MH in addition to VET and/or DM (MH + VET±DM); and C) women receiving no prophylaxis with MH, DM, or VET (NP) versus those MH in addition to VET and/or DM (MH + VET±DM)